FY2025 EPS Estimates for Alkermes Lowered by Leerink Partnrs

Alkermes plc (NASDAQ:ALKS) – Analysts at Leerink Partnrs cut their FY2025 EPS estimates for Alkermes in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn $1.50 per share for the year, down from their prior estimate of $1.55. The consensus estimate for Alkermes’ current full-year earnings is $2.23 per share. Leerink Partnrs also issued estimates for Alkermes’ FY2026 earnings at $1.84 EPS.

A number of other equities analysts also recently commented on the company. Piper Sandler restated an “overweight” rating and set a $37.00 target price (down previously from $38.00) on shares of Alkermes in a report on Friday, October 25th. Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and upped their price objective for the stock from $25.00 to $36.00 in a report on Tuesday, November 5th. The Goldman Sachs Group cut their target price on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. HC Wainwright reissued a “neutral” rating and issued a $37.00 price target on shares of Alkermes in a research note on Friday, October 25th. Finally, Mizuho lifted their price objective on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Alkermes currently has an average rating of “Moderate Buy” and an average price target of $36.00.

Alkermes Trading Up 1.0 %

ALKS opened at $31.56 on Thursday. The firm has a market capitalization of $5.11 billion, a price-to-earnings ratio of 16.18, a PEG ratio of 1.56 and a beta of 0.49. Alkermes has a one year low of $22.90 and a one year high of $32.88. The business has a 50 day simple moving average of $29.66 and a two-hundred day simple moving average of $28.22. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03.

Insider Activity

In related news, Director Cato T. Laurencin sold 2,691 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the transaction, the director now directly owns 23,013 shares of the company’s stock, valued at approximately $732,964.05. This represents a 10.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Craig C. Hopkinson sold 10,471 shares of Alkermes stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total value of $309,208.63. Following the completion of the sale, the executive vice president now directly owns 99,238 shares of the company’s stock, valued at approximately $2,930,498.14. The trade was a 9.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 147,738 shares of company stock worth $4,572,904 over the last three months. 4.89% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alkermes

A number of hedge funds have recently bought and sold shares of the business. Handelsbanken Fonder AB boosted its holdings in shares of Alkermes by 0.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 220,600 shares of the company’s stock valued at $6,175,000 after acquiring an additional 700 shares during the last quarter. Nicollet Investment Management Inc. boosted its holdings in Alkermes by 1.7% in the third quarter. Nicollet Investment Management Inc. now owns 43,845 shares of the company’s stock worth $1,227,000 after purchasing an additional 714 shares during the last quarter. KBC Group NV grew its position in Alkermes by 18.8% in the 3rd quarter. KBC Group NV now owns 4,890 shares of the company’s stock worth $137,000 after purchasing an additional 774 shares during the period. Exchange Traded Concepts LLC lifted its holdings in shares of Alkermes by 3.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 30,950 shares of the company’s stock valued at $890,000 after buying an additional 897 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Alkermes by 17.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,956 shares of the company’s stock worth $164,000 after buying an additional 904 shares during the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.